Flavio Vincenti, Oriol Bestard, Amarpali Brar, Josep M Cruzado, Daniel Seron, A Osama Gaber, Nicole Ali, Anat R Tambur, Helen Lee, Giovanni Abbadessa, Jo-Anne Paul, Markus Dudek, Ruby J Siegel, Alba Torija, Dorothée Semiond, Lucie Lépine, Nils Ternes, Robert A Montgomery, Mark Stegall
SIGNIFICANCE STATEMENT: There is no standardized desensitization regimen for kidney transplant candidates. CD38, expressed by plasma cells, could be targeted for desensitization to deplete plasma cells producing alloantibodies and donor-specific antibodies. Few studies and case reports are available regarding the use of CD38 antibodies for desensitization in patients awaiting kidney transplant. This study shows that isatuximab, a CD38-targeting therapy, was well tolerated in kidney transplant candidates, with a durable decrease in anti-HLA antibodies and partial desensitization activity...
March 1, 2024: Journal of the American Society of Nephrology: JASN